logo
Cannabis use raises risk of heart attack and stroke more than cocaine, other drugs, major review suggests

Cannabis use raises risk of heart attack and stroke more than cocaine, other drugs, major review suggests

Fox News19-06-2025

The potential risk of cannabis use has been in the spotlight following recent research pointing toward negative health effects.
This includes a new meta-analysis by French researchers, published in the journal Heart, which reviewed multiple studies to assess the link between cannabis and major adverse cardiovascular events (MACE).
The researchers analyzed data from more than 400 million patients involved in 24 previous cross-sectional studies (capturing data at a single point in time) and cohort studies (following patients over time). One study focused on medical cannabis.
The overall results noted a significant increase in risk of major cardiovascular events, including a 29% higher likelihood of heart attack, 20% higher risk of stroke and twice the chances of cardiovascular death.
The danger was also elevated in people who used cannabis at least once a week.
Several studies found higher odds of acute myocardial infarction, commonly known as a heart attack.
One study pinpointed the risk among younger populations aged 15 to 22, while another observed it in patients who used cannabis more than once a week.
One study from the primary French administrative database for hospitals found that, compared to other illicit drugs like cocaine and opioids, cannabis was a larger predictor of heart attack.
Another study analyzed the association between cannabis and acute coronary syndrome (reduced blood flow to the heart) in nearly 15,000 patients ranging from 18 to 54 years old.
The analysis found no significant association in the overall sample, but signaled a higher risk in a subgroup of patients aged 18 to 36.
Cannabis use significantly increased all-cause mortality and cardiovascular mortality in a cohort of patients who experienced a heart attack before age 50.
A UK Biobank analysis pointed out that women have a "significantly higher" risk of cardiovascular mortality than men.
The larger review concluded that these findings reveal "positive associations" between cannabis use and MACE, and should "encourage investigating cannabis use in all patients presenting with serious cardiovascular disorders."
Although medical marijuana can provide relief for people with conditions like arthritis, multiple sclerosis, cancer and other illnesses, overuse has been linked to potential health risks, especially for seniors.
The authors of the French review acknowledged that there were some limitations to the findings – primarily that there is a lower prevalence of cocaine and opioids compared to cannabis use.
"Cannabis exposure was poorly reported in the included studies, which prevented our meta-analysis from assessing it," they wrote.
There was also a potential for some degree of bias in some of the studies due to lack of information or missing data.
"Studies that relied on patient surveys faced substantial bias regarding exposure and outcome misclassification when patients assessed these data themselves," the researchers noted.
Other potential limitations included overlapping data and limited timeframes.
During an appearance on "America's Newsroom" in early June, Fox News senior medical analyst Dr. Marc Siegel commented on a recent study that found more seniors are using cannabis than ever before, despite the potential health risks.
Siegel noted that regular use of cannabis can be dangerous if not tracked.
"We definitely jumped the gun by not anticipating all the medical risks here."
"You might use a gummy to go to bed, and then the next thing, you're using two gummies, or three gummies, and it could increase anxiety, it can increase discombobulation, you're not thinking clearly, ER visits are on the increase," he cautioned.
"We know about problems with the lungs," Siegel added. "It can accelerate dementia and can affect behavior."
The doctor likened the use of marijuana to the effects of smoking cigarettes in terms of damage to the heart and lungs.
"It is absolutely an active chemical we need to watch out for, and I'm very disturbed that the elderly are using it," he said.
"We've completely jumped the gun [on legalization] because people are going to the ER with psychosis. They're going there with vomiting disorders. They're having car accidents as a result," he went on.
For more Health articles, visit www.foxnews.com/health
"We are studying Colorado ever since it was legalized there, and the results are not pretty. We definitely jumped the gun by not anticipating all the medical risks here."
Fox News Digital reached out to the study authors for comment.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors
Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors

Yahoo

time3 hours ago

  • Yahoo

Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors

Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the appointment of Dr. Joon Sup Lee as an independent director to its Board of Directors. The appointment went into effect on June 18, 2025. A healthcare specialist in the laboratory testing an Oncology-related product. Dr. Lee's appointment was a result of Medtronic increasing the size of its Board. The new director will serve on the Board's Science and Technology Committee and the Compensation and Talent Committee. Dr. Lee is currently the CEO of Emory Healthcare, Inc., overseeing Georgia's most comprehensive academic health system. Before joining Emory Healthcare, Dr. Lee was the executive director of the University of Pittsburgh Medical Center's (UPMC) Heart and Vascular Institute from 2018 to 2020. He was also a professor of medicine at the University of Pittsburgh School of Medicine. He held various leadership roles at UPMC, including Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory. Medtronic plc (NYSE:MDT) is an Irish-domiciled healthcare technology company. It develops and sells medical devices and therapies for chronic conditions across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its top products include heart devices, spinal implants, surgical tools, insulin pumps, and neuromodulation systems. Medtronic serves over 79 million patients annually in more than 150 countries. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment

Yahoo

time4 hours ago

  • Yahoo

GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

Yahoo

time4 hours ago

  • Yahoo

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the shares of Regulus ceased trading on the NASDAQ exchange, and the company became a fully owned subsidiary of Novartis. lucarista/ The acquisition marks a crucial step in the company's effort to advance the clinical development of a potential first-in-class medicine for autosomal dominant polycystic kidney disease. Regulus Joins Novartis with Farabursen, an investigational next-generation oligonucleotide aiming to reduce the growth of cysts and kidney size. Novartis is a global healthcare company dedicated to discovering and developing innovative medicines that improve and extend people's lives. It also focuses on addressing significant medical challenges, including cancer and rare genetic disorders, by prioritizing research and development, as well as innovative access approaches. Novartis AG (NYSE:NVS) is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines to improve and extend people's lives. It also focuses on using science-based innovation to address significant healthcare challenges. Novartis operates in over 100 countries, with the US accounting for about one-third of its revenue. While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store